• Targovax Receives Fast-Track Designation for ONCOS-102 americanpharmaceuticalreview
    February 19, 2021
    Targovax has announced its lead clinical candidate ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the U.S. Food and Drug Administration (FDA).
PharmaSources Customer Service